Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016', provides in depth analysis on Melanocortin Receptor 4 (MC4R) targeted pipeline therapeutics. 

The report provides comprehensive information on the Melanocortin Receptor 4 (MC4R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R) 
- The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Melanocortin Receptor 4 (MC4R) Overview 7
Therapeutics Development 8
Melanocortin Receptor 4 (MC4R) - Products under Development by Stage of Development 8
Melanocortin Receptor 4 (MC4R) - Products under Development by Therapy Area 9
Melanocortin Receptor 4 (MC4R) - Products under Development by Indication 10
Melanocortin Receptor 4 (MC4R) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Melanocortin Receptor 4 (MC4R) - Products under Development by Companies 14
Melanocortin Receptor 4 (MC4R) - Products under Development by Universities/Institutes 16
Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development 25
AstraZeneca Plc 25
Mallinckrodt Plc 26
Obexia AG 27
Palatin Technologies, Inc. 28
Pfizer Inc. 29
Retrophin Inc. 30
Melanocortin Receptor 4 (MC4R) - Drug Profiles 31
(liraglutide + setmelanotide) - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
AQB-565 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
bremelanotide - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
corticotropin - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
cosyntropin - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
OBX-1201 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
PL-8905 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Proteins to Agonize MC4R for Obesity - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
setmelanotide - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Agonize MC4-R for Obesity - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Melanocortin Receptor 4 (MC4R) - Dormant Projects 50
Melanocortin Receptor 4 (MC4R) - Discontinued Products 52
Melanocortin Receptor 4 (MC4R) - Featured News & Press Releases 53
Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder 53
Jul 20, 2016: Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity 53
Jul 05, 2016: Health Care Resource Use and Costs of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse 54
Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies' New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors 55
Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus 56
Jun 06, 2016: Palatin Technologies Receives U.S. Patent Strengthening Its Melanocortin Peptide Intellectual Property 57
May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome 58
Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting 58
Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction 59
Jan 07, 2016: Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity 59
Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome 60
Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction 60
Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus 60
Nov 06, 2015: Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity 62
Nov 06, 2015: Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity 62
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Comparative Analysis by Unknown Stage Development, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Pipeline by AstraZeneca Plc, H2 2016 25
Pipeline by Mallinckrodt Plc, H2 2016 26
Pipeline by Obexia AG, H2 2016 27
Pipeline by Palatin Technologies, Inc., H2 2016 28
Pipeline by Pfizer Inc., H2 2016 29
Pipeline by Retrophin Inc., H2 2016 30
Dormant Projects, H2 2016 50
Dormant Projects (Contd..1), H2 2016 51
Discontinued Products, H2 2016 52